ANXA2 and ovarian cancer: For example, using high-density protein microarrays, Gnjatic et al. [56] identified a number of highly prognostically discriminative TAA-AAbs signatures associated with either favorable (ANXA2 + FAM13B + FER + ZIM2 in ovarian cancer and GAS2 + HERPUD1 + TMOD1 + TMSB10 in pancreatic cancer) or poor (ERRFI1 + PHLDB1 + TRH + TRUB1 in ovarian cancer and CRYBB2 + NR2E3 + PTPRA + ZNF695 for pancreatic cancer) outcomes.